


Eragidomide

Cat. No.:	HY-130800		
CAS No.:	1860875-51-9		
Molecular Formula:	C ₂₂ H ₁₈ ClF ₂ N ₃ O ₄		
Molecular Weight:	461.85		
Target:	Ligands for E3 Ligase; Apoptosis; Molecular Glues		
Pathway:	PROTAC; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (216.52 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	2.1652 mL	10.8260 mL	21.6521 mL
	5 mM	0.4330 mL	2.1652 mL	4.3304 mL
	10 mM	0.2165 mL	1.0826 mL	2.1652 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution 			

BIOLOGICAL ACTIVITY

Description	Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4 ^{CRBN} to selectively target GSPT1 for ubiquitination and proteasomal degradation ^{[1][2]} .
IC₅₀ & Target	Cereblon
In Vitro	Depletion of GSPT1 by Eragidomide rapidly induces acute myeloid leukemia (AML) apoptosis, reducing leukemia engraftment and leukemia stem cells (LSCs) in large-scale primary patient xenografting of 35 independent AML samples.

Eragidomide activity is mediated by multiple layers of signaling networks and pathways within AML blasts and LSCs^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Chem Biol. 2022 Nov 3.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Christine Surka, et al. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood. 2021 Feb 4;137(5):661-677.
- [2]. Joshua D Hansen, et al. CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2021 Feb 25;64(4):1835-1843.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA